Sudarshan Sukhani of s2analytics.com told CNBC-TV18, “Glenmark Pharma charts are attractive. It is outperforming the broad market, doing very well in its sector. I would say that the investor should hold on to this share. It is one of the best quality. What is the possible target for that is a little difficult but I would expect the stock to touch Rs 700 in the next two years or more.”
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
